Needham & Company LLC Reaffirms Buy Rating for Tempus AI (NASDAQ:TEM)

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating restated by stock analysts at Needham & Company LLC in a research report issued on Monday, MarketBeat Ratings reports. They presently have a $75.00 target price on the stock. Needham & Company LLC’s price objective points to a potential upside of 53.12% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Tempus AI in a report on Wednesday, June 17th. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Wolfe Research began coverage on Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Jefferies Financial Group began coverage on Tempus AI in a research report on Monday, April 13th. They issued an “underperform” rating and a $35.00 price objective for the company. Finally, BTIG Research reissued a “buy” rating and set a $80.00 target price on shares of Tempus AI in a research note on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Tempus AI has an average rating of “Hold” and a consensus target price of $68.92.

Tempus AI Trading Up 1.2%

Shares of NASDAQ TEM opened at $48.98 on Monday. Tempus AI has a twelve month low of $41.73 and a twelve month high of $104.32. The stock has a market cap of $8.80 billion, a price-to-earnings ratio of -28.48 and a beta of 3.46. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The company’s fifty day moving average is $51.64 and its 200-day moving average is $53.84.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The business had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm’s quarterly revenue was up 36.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.24) EPS. Equities research analysts predict that Tempus AI will post -1.35 EPS for the current year.

Insiders Place Their Bets

In other Tempus AI news, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction on Monday, June 29th. The shares were sold at an average price of $57.48, for a total value of $9,556,050.00. Following the sale, the chief executive officer directly owned 8,775,283 shares in the company, valued at approximately $504,403,266.84. The trade was a 1.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James William Rogers sold 11,529 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00. Following the sale, the chief financial officer directly owned 114,866 shares in the company, valued at $6,317,630. This trade represents a 9.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 616,043 shares of company stock valued at $31,748,593 over the last 90 days. 24.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tempus AI

Several hedge funds have recently modified their holdings of TEM. JPL Wealth Management LLC bought a new stake in Tempus AI during the third quarter worth about $26,000. Los Angeles Capital Management LLC bought a new position in Tempus AI in the fourth quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd bought a new position in Tempus AI in the third quarter valued at approximately $38,000. Whittier Trust Co. increased its position in shares of Tempus AI by 190.0% during the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after purchasing an additional 570 shares during the last quarter. Finally, Lodestone Wealth Management LLC acquired a new position in shares of Tempus AI during the 4th quarter worth approximately $42,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: The Personalis acquisition could deepen Tempus AI’s position in precision oncology and expand its addressable market in cancer monitoring. Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring
• Positive Sentiment: Needham reaffirmed a Buy rating and set a $75 price target, suggesting analysts still see meaningful upside despite the transaction-related selloff. Needham on Tempus AI Inc (TEM): ‘Buyers of any weakness related to the transaction’
• Neutral Sentiment: Tempus said it signed a definitive merger agreement to acquire Personalis, giving investors more clarity on the structure and terms of the deal. Tempus AI Announces Merger Agreement to Acquire Personalis
• Negative Sentiment: The market is reacting cautiously to the size of the deal, likely due to dilution, integration risk, and the fact that both stocks fell after the announcement. Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.